Valion Bio, Inc.
VBIOHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeValion Bio, Inc. operates as a late-stage biopharmaceutical company. At a $2.0M market cap, Valion Bio, Inc. ranks as a micro-cap company within healthcare. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome.
Market Cap
$2.0M
Beta
1.80
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-177.91
EPS (Fwd)
—
ROE
-459.5%
ROA
-57.1%
Cash
$2.1M
Total Debt
$17.4M
Free CF
-$8.1M
52W Change
-98.7%
Annual Financials
Cash vs Debt
Where VBIO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, VBIO finished 91.39% below its 150-day moving average ($13.48) and 93.01% below its 200-day moving average ($16.59). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VBIO overbought or oversold?
At the October 20, 2026 close, VBIO's RSI(14) was 5.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, VBIO has $2.1M in cash with $17.4M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$8.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -459.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $1.8M (2022) to $0 (2025), a 100% decline worth watching.
Valion Bio, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Valion Bio, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VBIO.